Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2016

View Archived Issues

Yisheng completes phase I trial of PIKA hepatitis B vaccine

Taisho Pharmaceutical's TP-0463518 in clinical development for renal anemia

CRISPR/Cas9 gene editing advances, first patient receives cells with edited genes

Oral, ultra-long-acting form of ivermectin achieves sustained therapeutic serum drug concentrations

Chiesi Farmaceutici acquires Atopix Therapeutics

Karolinska Development company raises funds to advance development of GR-3027

Eli Lilly Japan and Torii Pharmaceutical launch Taltz in Japan

BioLineRx inlicenses project for dry eye syndrome

KalVista Pharmaceuticals closes merger with Carbylan

Immunovaccine's DPX-Survivac wins EMA orphan drug designation

ENDURANCE-4 trial shows efficacy of glecaprevir/pibrentasvir in HCV genotypes 4-6

Ability Pharmaceuticals begins phase II study of ABTL-0812

FDA issues complete response letter for Green Cross's IVIG-SN

Enamine and Pcovery extend collaboration

Phase III trial of mepolizumab for eosinophilic granulomatosis with polyangiitis meets endpoints

Gates Foundation grant supports NovoBiotic's work on orally active analogues of teixobactin for TB

Cancer candidate PRI-724 shows antifibrotic potential in patients with HCV and cirrhosis

Farnesoid X receptor agonist LJN-452 well tolerated in first-in-human study

Acorda ends development of dalfampridine to improve post-stroke walking difficulties

FDA grants orphan drug designation to PQR-309

Primary endpoint not met in phase III study of solanezumab for mild dementia due to Alzheimer's

Ruga Corporation changes name to Aravive Biologics

Rgenix patents SLC6A8 inhibitors for cancer

University of Colorado patent reveals beta-lactam antibiotic sensitizers

AstraZeneca describes LTC4 synthase inhibitors

Chiesi Farmaceutici reports compounds for asthma and COPD

Bayer Healthcare divulges TNKS1/TNKS2 inhibitors for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...